Influence of type 2 sodium-glucose co-transporter inhibitors (dapagliflozin) on the indicators of total mortality in patients with type 2 diabetes (CARDIA-MOS study, Moscow)

Influence of type 2 sodium-glucose co-transporter inhibitors (dapagliflozin) on the indicators of total mortality in patients with type 2 diabetes (CARDIA-MOS study, Moscow)

BACKGROUND: The widespread use in clinical practice of drugs with cardio- and nephroprotective properties, in particular, sodium-glucose cotransporter type 2 inhibitors (SGLT2i), is based on the results of large-scale international randomized trials. Meanwhile, there are no data demonstrating the po...

Full description

Bibliographic Details
Main Authors: M. B. Antsiferov, N. A. Demidov, M. A. Balberova, O. V. Lobanova, I. G. Mudrikova, D. G. Gusenbekova
Format: Article
Language:English
Published: Endocrinology Research Centre 2022-12-01
Series:Сахарный диабет
Subjects:
type 2 diabetes mellitus
dapagliflozin
sglt2i
relative risk of death
cvd
chf
ckd
Online Access:https://www.dia-endojournals.ru/jour/article/view/12929

Internet

https://www.dia-endojournals.ru/jour/article/view/12929

Similar Items